Cox proportional hazard model, there were an improvement of local-regional relapse-free survival (p = 0.0050), and a trend of better overall survival (p = 0.0762) with the use of adjuvant chemoradiotherapy. In a subgroup analysis on patients with nodal involvement (n = 38), the use of chemoradiotherapy was correlated with increased overall and local-regional relapse-free survival on multivariate analysis (p = 0.0235 and 0.0095, respectively). The benefit of adjuvant chemoradiotherapy was significant for local-regional relapse-free survival (p = 0.0319), but not for overall survival (p = 0.4544) in patients with T3/T4 disease (n = 40).
Conclusions: Adjuvant chemoradiotherapy enhances locoregional control, and possibly overall survival in patients with ampulla of Vater cancer after curative resection.

3552 POSTER

Impact of the body mass index on the outcome of patients with cancer of the esophagogastric junction after surgical resection

G. Schumacher, N. Schlechtweg, S.J. Presser, P. Neuhaus. *Charité Humboldt-University zu Berlin, General- Visceral- and Transplantation Surgery, Berlin, Germany*

According to the classification of Siewert, cancer of the gastroesophageal junction is subdivided into Type I, II, or III dependent on its localization. Type I cancers are considered to be distal esophageal cancers, which are treated with esophageal resection. Type II and III cancers are considered to be gastric cancers and are treated with extended gastrectomy including resection of the distal esophagus. We were interested to evaluate the impact of body mass index (BMI) on postoperative complications, length of stay in the ICU, total hospital stay, and overall survival.
From 2000 to 2006, 108 patients with cancer of the esophagogastric junction were operated in our department. We divided the patients into two groups according to BMI. Fifty-six patients (52%) presented with a BMI below 25 kg/m2 (group 1) and fifty-two patients (48%) above 25 kg/m2 (group 2). Type I cancers (n = 26; 24%) were equally distributed between groups 1 and 2 with 13 patients in each group. Type II cancers (n = 61; 56%) were the most frequent types and occurred more often in group 2 (34 vs 27), and Type III cancers (n = 21; 19%), had a higher prevalence in group 1 (16 vs 5).
Pulmonary complications were observed in 33 patients (respiratory in sufficiency n = 12, pneumonia n = 12, bronchitis n = 7, lung embolism n = 2). There was no statistically significant difference between groups 1 and 2. However, both lung embolisms were seen in group 2. Eighteen patients developed surgical complications (anastomotic leakage n = 7, chylus fistula n = 1, intraabdominal abscess n = 3, intrapleural abscess n = 2, abscess of the abdominal wall n = 3, and bleeding n = 2). There was also no statistically significant difference between groups 1 and 2. Functional complications occurred in 29 patients (dysphagia n = 5, nausea n = 5, heart burn n = 4, impaired enteral nutrition n = 6, vomiting n = 9). We found no statistically significant difference between groups 1 and 2. However, impaired enteral nutrition and vomiting was observed more frequent in group 2. The median time in the ICU was 3 days in group 1, and 5 days in group 2 (p = 0.021). The median hospitalization time was 14 days in both groups. Overall survival after a follow up of 42 months was 34% in group 2 and 25% in group 1 (p = 0.961). Recurrence free survival was 48% in group 1 and 42% in group 2 (p = 0.596).
Our data show that surgery for cancer of the cardia can be performed independent of the BMI.

3553 POSTER

Phase I/II study of S-1 in patients (pts) with advanced hepatocellular carcinoma (HCC): Results of phase I part – Correlation between pharmacokinetics (PK) and hepatic dysfunction

J. Furuse[1], T. Okusaka[2], H. Ishii[1], K. Nakachi[1], E. Suzuki[1], S. Shimizu[1], H. Ueno[2], M. Ikeda[2], C. Morizane[2], T. Ogura[2]. *[1]National Cancer Center Hospital East, Division of Hepatobiliary and Pancreatic Oncology, Kashiwa, Japan; [2]National Cancer Center Hospital, Division of Hepatobiliary and Pancreatic Oncology, Tokyo, Japan*

Background: S-1 is an oral formulation combining tegafur (FT), gimeracil (CDHP), and oteracil potassium (Oxo). The standard dose is 80 mg/m^2 bid for gastrointestinal, head and neck, breast, and lung cancers in Japan. The liver plays an important role in the conversion of FT to 5-FU, as well as the degradation of 5-FU. S-1 is expected to be effective against HCC, but nearly all pts with HCC have hepatic dysfunction. This study was designed to examine the correlation between the PK of S-1 and hepatic dysfunction and to determine the recommended dose of S-1 for pts with advanced HCC. In addition, we compared PK parameters in pts with HCC with those in patients with pancreatic cancer (PC) and biliary tract cancer (BTC).
Materials and Methods: Eligibility criteria were advanced HCC, unresectable/incurable by ablation or TACE, pathological and/or clinical confirmation of the diagnosis, at least one measurable lesion, an ECOG performance status (PS) of 0 to 2, Child-Pugh class A or B, adequate organ functions, and written consent. The starting dose of S-1 (level 1) was about 64 mg/m^2 bid (80% of standard dose) on days 1−28 of a 42-day cycle. Level 2 was 80 mg/m^2. A standard 3+3-design and standard definitions of DLT were employed. PK analyses were performed to determine the plasma concentrations of the S-1 components (FT, CDHP, and Oxo) and 5-FU on days 1 and 8. The PK parameters were compared with those in 8 pts with PC and 8 pts with BTC who were enrolled in each phase II trial.
Results: Nine pts with HCC (level 1: 3 pts, level 2: 6 pts), including 3 with Child-Pugh class B were enrolled. All pts had a PS of 0. The most common toxicities were thrombocytopenia, leukopenia, neutropenia, and anorexia. > Grade 3 toxicity was rare. There was no DLT at level 1. At level 2, DLT occurred in 2 pts with Child-Pugh class B. One had grade 3 anorexia, and the other had grade 2 rash, requiring more than 8 consecutive days of rest. There were no significant differences in PK parameters among pts with Child-Pugh class A, B, and the 16 pts with PC and BTC. Two pts (level 1: 1 pt, level 2: 1 pt) had a partial response, giving an overall response rate of 22% (2/9).
Conclusions: Hepatic dysfunction (Child-Pugh class A or B) did not significantly affect the PK parameters of S-1 or its metabolites. Although S-1 should be carefully given to pts with Child-Pugh class B, S-1 at 80 mg/m^2 bid is tolerated in pts with advanced HCC. This dose is recommended for the phase II part of this study.

3554 POSTER

Phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX-4) for gastric cancer patients with malignant ascites

H. Yoo[1], S. Oh[1], H. Kwon[1], S. Lee[1], D. Lee[1], S. Kim[1], J. Jang[1], M. Kim[2], J. Jeong[3], H. Kim[1]. *[1]Dong-A University Medical Center, department of internal medicine, Busan, Korea; [2]Dong-A University Medical Center, department of surgery, Busan, Korea; [3]Dong-A University Medical Center, department of pathology, Busan, Korea*

Background: The clinical study about chemotherapy of gastric cancer patients with malignant ascites had limited because peritoneal seeding is not defined measurable lesion and generally patients had poor performance status. We evaluate the efficacy and toxicity of fortnightly modified FOLFOX-4 regimen in patients with peritoneal disseminated gastric cancer.
Methods: Gastric cancer patients who had cytologically confirmed malignant ascites were treated with cycles of oxaliplatin 85 mg/m^2 on day 1 plus leucovorin 20 mg/m^2, followed by 5-FU a 400 mg/m^2 bolus and a 22 hour continuous infusion of 600 mg/m^2 5-FU on days 1−2 every 2 week intervals.
Results: Forty-eight patients were enrolled in this study. Male to female ratio was 2:1. Median age was 47 (31−76). 22 patients (45.8%) were treated with modified FOLFOX-4 as a 1st line palliative treatment. 21 patients (43.8%) had ECOG performance status 2. 36 patients were assessable with measurable lesion. Twelve of the 36 patients demonstrated partial responses (PR). Ascties amount decreasing or disappearance was observed 17 (35.4%) patients. The median time to progression and overall survival time were 3.5 months (95% CI: 2.9−4.1 months) and 8.4 months (95% CI: 4.9−11.9 months), respectively. Totally 233 cycles of chemotherapy were done. Major hematologic toxicities included grade 1−2 anemia (53.9%), neutropenia (41.6%) and grade 3−4 neutropenia (15.8%). Six cycles were associated with neutropenic fever. The most common non-hematological toxicities were grade 2 and 3 nausea/vomiting (17%). There was no treatment related death.
Conclusion: Even though gastric cancer patient with malignant ascites accompanied poor performance status, modified FOLFOX-4 regimen was found to be a safe and effective.

3555 POSTER

The efficacy of early ^{18}F-fluorodeoxyglucose positron emission tomography following completion of definitive chemoradiotherapy in patients with esophageal carcinoma

K. Takeda, K. Jingu, H. Ariga, M. Kotoh, T. Sakayauchi, K. Fujimoto, T. Metoki, K. Narazaki, Y. Ogawa, S. Yamada. *Tohoku University, Therapeutic radiology, Sendai, Japan*

Background: To assess the value of early ^{18}F-fluorodeoxyglucose positron emission tomography (FDG-PET) scans following definitive chemoradiotherapy (CRT) in predicting clinical local response (CLR) or local relapse-free survival (LRFS) of esophageal cancer patients.
Methods and Materials: We retrospectively analyzed 25 esophageal cancer patients who were treated with curative CRT between January 2005 and December 2006. Median age of patients was 60 years (range,